- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06125678
Correlation of Cross Sectional Imaging and Small Intestinal Contrast Ultrasonography in Known Crohn's Disease (CACTUS-CD)
November 18, 2023 updated by: Asian Institute of Gastroenterology, India
Correlation and Assessment of Small Bowel Lesion Using Cross Sectional Imaging Techniques Compared to Small Intestinal Contrast Ultrasonography in Known Small Bowel Crohn's Disease(the CACTUS-CD Trial): a Prospective Study
Small intestinal contrast ultrasound (SICUS) is a modality of intestinal ultrasound (IUS) which does not require any parenteral administration of contrast agent but requires ingestion of around 500 ml of polyethylene glycol (PEG).
SICUS does not involve any radiation.
Computed tomography enteroclysis (CTE) requires colonic cleansing using polyethylene glycol (PEG) followed by infusion of 1.5 litres of PEG via a nasal catheter to distend and properly visualise the small intestine.
CTE although accurate for assessing response to therapy and transmural healing in small bowel CD is associated with radiation and adds to cost of management.
Magnetic resonance enterography (MRE) using PEG followed by 2 liters of oral fluid with mannitol was administered to distend and properly visualize the small intestine.
MRE although accurate for assessing response to therapy and transmural healing in small bowel CD is associated with radiation and adds to cost of management.
On the other hand, SICUS is relatively non-invasive method of small bowel assessment although the accuracy has not been studied prospectively.
An earlier retrospective study in which MRE/CTE and SICUS are done within 3 months of each other, SICUS had identified lesions and complications in patients with CD with high levels of sensitivity, specificity, and accuracy compared to CT-enteroclysis (3).
These findings need prospective validation.
The accuracy of SICUS may be suboptimal due to constant peristalsis in the small intestine.
Hence the investigators planned this study to perform SICUS in patients with small bowel CD who otherwise require a MRE/CTE for disease monitoring on the same day before the procedure with the same PEG preparation.
If SICUS findings are found to correlate with MRE/CTE findings intros study, SICUS have the potential to replace other modalities for monitoring of small bowel Crohn's disease (CD) and emerge as a cost-effective, easy alternative.
The investigators also want to understand the drawbacks and limitations of SICUS in this scenario.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Diagnosis, CD site and patient's management shall be made according generally accepted recommendations(4).
SICUS shall be performed in all participants by one independent experienced operator (MAM).
Colonic cleansing shall be done on night before the examination with Polyethylene glycol (PEG) solution (1 litre).
The participants shall be examined after the ingestion of 375 mL (range 250-500 mL) of polyethylene glycol (PEG) in the morning using a convex transducer (2-6 MHz) and a high frequency linear-array transducer for details (5-14 MHz).
Median SICUS duration shall be noted.
SICUS shall be performed without any additional charges to the participant.
CT-Enteroclysis shall be performed in all participants by one independent experienced operator (UK).
A 20G needle shall be placed in an antecubital vein and 8-F nasojejunal catheter with aTeflon-covered guide wire shall be positioned under fluoroscopic guidance with the distal extremely located in the distal duodenum/proximal jejunum.
Afterward the patient shall be taken into the CT room where hypodense contrast material (1500 mL of PEG) shall be administered manually with 60-mL syringes, with a constant and continuous injection rate of 150 mL/min followed by a flow rate of 200 mL/min until the maximum tolerance of the patient.
Just before the examination participants shall receive a smooth muscle relaxant (N butyl 4 scopolamine) to prevent spasms, achieve uniform small bowel distension, and reduce abdominal discomfort.
The study shall be performed by a 64-slice multidetector CT with the following scan parameters: collimation 1.25 mm, table feed 39.37 mm/rot, 120 kV, 300 mAs,pitch 0.984:1, rotation time 0.5 s, time of acquisition 12.5 s, FOV 50 cm, matrix 512x512.
After the infusion of PEG, CT scan seal be performed before and after the administration of intravenous iodinated contrast material.
The contrast-enhanced study shall be acquired 70s after the administration of contrast material (Ultravist 370, Schering AG, Berlin, Germany).
Median CT-Enteroclysis duration shall be recorded.
Magnetic Resonance enterography (MRE) shall be performed in all participants by one independent experienced operator.
The participant shall be fasted for 4-6 h prior to the study.
In adults, 2 liters of oral fluid with mannitol shall be administered to distend the bowel loops.
Just before the examination participants shall receive a smooth muscle relaxant (Buscopan) to prevent spasms, achieve uniform small bowel distension, and reduce abdominal discomfort.
T2, BTFE(axial and coronal sequence),diffusion weighted imaging (DWI)(Coronal sequence), Post contrast (Axial, Coronals and sagittal sequence) will be taken.Median MRE duration shall be recorded.The site of small bowel involvement, maximal bowel wall thickness and complications like stricture and fistula detected by SICUS and MRE/CTE shall be collected and correlated.
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Partha Pal, Md, DrNB
- Phone Number: +91-8945906823
- Email: partha1986@yahoo.com
Study Contact Backup
- Name: Kanapuram Pooja, DPharm
- Phone Number: +91-7569640516
- Email: kanapurampooja41413@gmail.com
Study Locations
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Recruiting
- Asian Institute of Gastroenterology
-
Contact:
- Partha Pal, Md, DrNB
- Phone Number: +91-8945906823
- Email: partha1986@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with known small bowel CD beyond reach of standard endoscopy who warrants monitoring of disease status either due to assessment of response to therapy/relapse/new unexplained symptoms, persistent disease activity, prior to switching therapy or deciding on surgical management.
Exclusion Criteria:
- Obese patients with poor ultrasound window
- pregnant/lactating mother
- Not willing for CT or enteroclysis examination
- Renal insufficiency precluding CT
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Small intestinal contrast enhanced ultrasound followed by cross sectional imaging
Patients shall be undergoing small intestinal contrast enhanced ultrasound followed by cross sectional imaging
|
First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in management decision after cross sectional imaging compared to ultrasound
Time Frame: Day 1
|
Percentage of patients in which cross sectional imaging changed the management decision
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Agreement for extent of involvement in affected area of small intestine between small intestinal contrast ultasound and cross sectional imaging
Time Frame: Day 1
|
Percentage of patients in which small intestinal ultrasound correctly identified extent of involvement compared to cross sectional imaging
|
Day 1
|
Agreement for detecting complications between small intestinal contrast ultrasound and cross sectional imaging
Time Frame: Day 1
|
Percentage of patients in which small intestinal ultrasound correctly identified complications compared to cross sectional imaging
|
Day 1
|
Correlation between bowel wall thickness in affected area in small intestine between small intestinal contrast ultasonography and cross sectional imaging
Time Frame: Day 1
|
Correlation between bowel wall thickness in ultrasonography and cross sectional imaging based on correlation coefficient
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Partha Pal, MD, DrNB, Asian Institute of Gastroenterology and Asian Healthcare Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2023
Primary Completion (Estimated)
September 19, 2024
Study Completion (Estimated)
September 19, 2024
Study Registration Dates
First Submitted
November 5, 2023
First Submitted That Met QC Criteria
November 5, 2023
First Posted (Actual)
November 9, 2023
Study Record Updates
Last Update Posted (Actual)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 18, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AIG/IEC-BH&R 49 / 06.2023-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingOvarian Carcinoma | Malignant Ovarian NeoplasmUnited States
-
Royal Marsden NHS Foundation TrustCompleted
-
National Cancer Institute (NCI)RecruitingAdvanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7United States
-
john eisenbreyNational Cancer Institute (NCI)RecruitingRenal Cell Carcinoma | Recurrent Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
University Hospital, BordeauxCompletedVentricular Arrhythmias | Persistent Atrial FibrillationFrance
-
National Cancer Institute (NCI)RecruitingMetastatic Adrenal Gland Pheochromocytoma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Advanced Adrenal Gland Pheochromocytoma | Advanced Paraganglioma | Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | Stage...United States
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
University of WashingtonNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Cervical Undifferentiated Carcinoma | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage... and other conditionsUnited States, Hong Kong, Canada
-
University of WashingtonNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States